Last Price$61.4(0.0%)
Market Cap$7,773.1M
LTM Net Income margin
43.7%
5Y avg
35.8%
Biotechnology industry
median
(764.7%)
Stock quality & Intrinsic value
8/10
(0.1%) overvalued
Halozyme Therapeutics, Inc. Net Income margin
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income margin | (10,435.9%) | (1,502.6%) | (628.9%) | (555.2%) | (426.9%) | (390.8%) | (35.2%) | (126.5%) | (152.3%) | (90.8%) | (23.9%) | (70.2%) | 19.9% | (52.9%) | (36.9%) | 48.2% | 90.8% | 30.6% | 34.0% | 43.7% |
Overvalued or undervalued?
Check the intrinsic value for HALO
and see if it's the right time to invest.
Halozyme Therapeutics, Inc. (HALO) Net Income margin comparison analysis
General
LTM Net Income margin
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Halozyme Therapeutics, Inc.HALO
43.7%
22.4%
64.3%
43.7%
Median Peer Set
(2.3%)
14.8%
(19.3%)
7.5%
United Therapeutics CorporationUTHR
41.5%
23.6%
25.7%
41.5%
Royalty Pharma plcRPRX
37.9%
(3.8%)
(43.7%)
37.9%
Regeneron Pharmaceuticals, Inc.REGN
31.1%
8.3%
10.4%
31.1%
BioMarin Pharmaceutical Inc.BMRN
15.0%
18.0%
139.3%
15.0%
argenx SEARGX
(4.5%)
198.6%
(60.5%)
(24.1%)
Vertex Pharmaceuticals IncorporatedVRTX
(4.9%)
11.7%
N/A
(4.9%)
Alnylam Pharmaceuticals, Inc.ALNY
(12.4%)
23.0%
(38.6%)
(12.4%)
BioNTech SEBNTX
(24.2%)
(77.4%)
(89.7%)
24.4%
BeiGene, Ltd.BGNE
(95.0%)
73.7%
467.1%
(35.9%)
Summit Therapeutics Inc.SMMT
N/A
N/A
(68.7%)
N/A
HALO key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.1 0.0% | 1.0 671.8% | 3.8 287.0% | 8.8 130.7% | 13.7 56.0% | 13.6 (0.3%) | 56.1 311.7% | 42.3 (24.5%) | 54.8 29.5% | 75.3 37.5% | 135.1 79.3% | 146.7 8.6% | 316.6 115.8% | 151.9 (52.0%) | 196.0 29.1% | 267.6 36.5% | 443.3 65.7% | 660.1 48.9% | 829.3 25.6% | 1,015.3 22.4% |
| Cost of Goods Sold (COGS) | 0.1 | 0.4 | 0.2 | 0.3 | 0.3 | 1.0 | 0.3 | 1.1 | 6.2 | 22.7 | 29.2 | 33.2 | 31.2 | 10.1 | 45.5 | 43.4 | 81.4 | 139.3 | 192.4 | 159.4 |
% margin | 0.1 59.1% | 0.5 55.5% | 3.6 93.7% | 8.4 96.2% | 13.4 97.7% | 12.6 92.8% | 55.8 99.5% | 41.2 97.4% | 48.6 88.6% | 52.6 69.8% | 105.8 78.3% | 113.5 77.4% | 285.5 90.2% | 141.7 93.3% | 150.4 76.8% | 224.2 83.8% | 361.9 81.6% | 520.8 78.9% | 636.9 76.8% | 855.9 84.3% |
| Operating Expenses | 13.6 | 16.1 | 31.7 | 58.9 | 71.8 | 66.9 | 75.7 | 94.9 | 129.0 | 115.6 | 133.3 | 196.7 | 204.5 | 211.1 | 218.1 | 80.0 | 86.0 | 253.3 | 299.3 | 304.4 |
| Research & Development Expenses (R&D) | 10.2 | 9.2 | 20.6 | 44.2 | 56.6 | 51.8 | 57.6 | 70.0 | 96.6 | 79.7 | 93.2 | 150.8 | 150.6 | 150.3 | 140.8 | 34.2 | 35.7 | 66.6 | 76.4 | 79.0 |
| Selling, General & Administrative Expenses (SG&A) | 3.4 | 6.9 | 11.2 | 14.6 | 15.2 | 15.1 | 18.1 | 24.8 | 32.3 | 35.9 | 40.0 | 45.9 | 53.8 | 60.8 | 77.3 | 45.7 | 50.3 | 143.5 | 149.2 | 154.3 |
% margin | (13.6) (10,660.7%) | (15.6) (1,587.3%) | (28.2) (740.9%) | (50.4) (575.5%) | (58.5) (427.6%) | (54.3) (398.2%) | (19.8) (35.4%) | (53.6) (126.7%) | (80.4) (146.8%) | (63.0) (83.7%) | (27.5) (20.3%) | (83.2) (56.7%) | 81.0 25.6% | (69.3) (45.7%) | (67.6) (34.5%) | 144.3 53.9% | 275.9 62.2% | 267.5 40.5% | 337.6 40.7% | 551.5 54.3% |
| Interest Income | 0.0 | 0.0 | 0.0 | 1.7 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7.1 | 15.0 | 6.4 | 15.9 | 0.0 | 0.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.3 | 5.6 | 5.2 | 20.0 | 22.0 | 18.0 | 11.6 | 20.4 | 7.5 | 16.9 | 18.8 | 18.1 |
| Pre-tax Income | (13.3) | 0.0 | 0.0 | (48.7) | (58.4) | (53.2) | (19,769.9) | (53.6) | (83.5) | (68.4) | (32.2) | (101.9) | 61.6 | (79.8) | (72.3) | 129.3 | 248.5 | 248.9 | 348.3 | 557.1 |
% effective tax rate | (0.3) 2.2% | (0.8) 0.0% | (4.3) 0.0% | (0.1) 0.1% | 0.0 0.0% | (1.0) 1.9% | (1.2) 0.0% | (1.1) 2.1% | 2.0 (2.5%) | 3.8 (5.6%) | 3.5 (10.9%) | 1.2 (1.1%) | (1.4) (2.2%) | 0.5 (0.7%) | (0.0) 0.0% | 0.2 0.2% | (154.2) (62.0%) | 46.8 18.8% | 66.7 19.2% | 113.0 20.3% |
% margin | (13.3) (10,435.9%) | (14.8) (1,502.6%) | (23.9) (628.9%) | (48.7) (555.2%) | (58.4) (426.9%) | (53.2) (390.8%) | (19.8) (35.2%) | (53.6) (126.5%) | (83.5) (152.3%) | (68.4) (90.8%) | (32.2) (23.9%) | (103.0) (70.2%) | 63.0 19.9% | (80.3) (52.9%) | (72.2) (36.9%) | 129.1 48.2% | 402.7 90.8% | 202.1 30.6% | 281.6 34.0% | 444.1 43.7% |
| EPS | (0.26) | (0.24) | (0.32) | (0.61) | (0.67) | (0.56) | (0.19) | (0.48) | (0.74) | (0.56) | (0.25) | (0.81) | 0.46 | (0.56) | (0.50) | 0.95 | 2.86 | 1.48 | 2.13 | 3.50 |
| Diluted EPS | (0.26) | (0.24) | (0.32) | (0.61) | (0.67) | (0.56) | (0.19) | (0.48) | (0.74) | (0.56) | (0.25) | (0.81) | 0.45 | (0.56) | (0.50) | 0.91 | 2.74 | 1.44 | 2.10 | 3.43 |
% margin | (13.4) (10,498.5%) | (14.5) (1,477.8%) | (28.2) (740.9%) | (49.4) (563.5%) | (56.9) (416.3%) | (52.7) (387.2%) | (18.7) (33.3%) | (52.5) (124.0%) | (79.0) (144.1%) | (61.0) (81.0%) | (25.4) (18.8%) | (79.5) (54.2%) | 83.2 26.3% | (69.3) (45.7%) | (56.6) (28.9%) | 153.0 57.2% | 259.0 58.4% | 315.5 47.8% | 451.9 54.5% | 656.5 64.7% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Halozyme Therapeutics, Inc.'s Net Income margin?
As of today, Microsoft Corp's last 12-month Net Income margin is 43.7%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Net Income margin for Halozyme Therapeutics, Inc. have been 50.1% over the past three years, and 37.6% over the past five years.
2) Is Halozyme Therapeutics, Inc.'s Net Income margin Good?
As of today, Halozyme Therapeutics, Inc.'s Net Income margin is 43.7%, which is higher than industry median of (764.7%). It indicates that Halozyme Therapeutics, Inc.'s Net Income margin is Good.